You are using an outdated browser. Please upgrade your browser to improve your experience.

You are using an outdated browser.

To ensure optimal security, this website will soon be unavailable on this browser. Please upgrade your browser to allow continued use of ACP websites.

Ischemic Vascular Disease: Use of Aspirin or Another Platelet

The percentage of patients 18-75 years of age who had a diagnosis of ischemic vascular disease (IVD) and were on daily aspirin or anti-platelet medication, unless allowed contraindications or exceptions are present.

Date Reviewed: November 4, 2018

Measure Info

MIPS 204NQF 0068CMS 204NQF EndorsedCQMC Core Measure
Measure Type: 
Process
Measure Steward: 
National Committee for Quality Assurance
Clinical Topic Area: 
Ischemic Vascular Disease

Care Setting: 
Outpatient
Data Source: 
Claims
CMS Web Interface
Electronic Health Records
Registry

ACP supports MIPS measure ID# TBD: “Vascular Disease: Use of Aspirin or Another Antiplatelet Therapy” because implementation will likely lead to meaningful and measureable improvements in clinical outcomes and also promote appropriate use of antiplatelet therapy in patients who are diagnosed with ischemic vascular disease (IVD). Furthermore, developers cite clinical recommendations of the American College of Cardiology and the American Heart Association for the “Management of Patients who are Diagnosed with IVD” to form the basis of the measure. Additionally, the numerator and denominator specifications are well defined and the denominator includes clinically appropriate exceptions to eligibility for the measure (i.e., patients who have a history of gastrointestinal bleeding, intracranial bleeding, bleeding disorder, allergy to aspirin or antiplatelet, or patients who are prescribed non-steroidal anti-inflammatory agent therapy). While we support this measure, we note that it may be difficult for clinicians who report this measure to capture over-the-counter aspirin therapy.

As part of an ongoing effort to improve user experience, we have made some updates to the Performance Measures section of ACP. Tell us what you think!